Tag
Kidney function influences certain Alzheimer’s disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD
This review evaluates brexpiprazole’s efficacy and safety for agitation in Alzheimer’s disease, revealing modest symptom improvement but uncertain safety profiles, underscoring the need for individualized therapy and further res
Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventiv
This review synthesizes evidence on clinically meaningful within-patient changes in cognitive and functional assessments among individuals transitioning to mild cognitive impairment (MCI), highlighting implications for clinical trials and e
Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits
Higher adherence to an anti-inflammatory diet is linked to lower all-cause mortality and a trend toward reduced Alzheimer’s disease mortality, particularly among men and non-Hispanic Whites, highlighting dietary modification as a pote
This article explores how genetic variants, plasma metabolites, and Mediterranean diet adherence interplay in modulating dementia risk and cognitive function, highlighting precision nutrition approaches for Alzheimer’s disease prevention.
A large prospective study reveals that adherence to a Mediterranean diet significantly lowers dementia risk, especially in individuals carrying two copies of the APOE4 gene associated with Alzheimer’s disease, highlighting the potential of
Recent research reveals that pathological tau can propagate from the brain to the colon through the vagal efferent pathway in Alzheimer’s disease, supporting a novel brain-to-gut axis involvement in disease progression and gut functio
The FDA has approved a subcutaneous form of lecanemab for maintenance therapy in early Alzheimer’s, offering similar clinical benefits to IV dosing with improved convenience and safety, potentially transforming patient care delivery.
This review synthesizes mechanistic, preclinical, and clinical evidence on 40 Hz light stimulation as a novel therapeutic approach to slow Alzheimer’s disease progression, highlighting safety, efficacy, and modality comparisons.
Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.
A Nature study links lithium deficiency in the brain to Alzheimer’s onset and shows lithium orotate reverses memory loss in mice, offering new hope for Alzheimer’s therapy.
Multi-ancestry polygenic risk scores significantly improve Alzheimer’s disease risk prediction in Hispanic populations compared to traditional single-ancestry models and APOE genotyping alone.
An in-depth overview of Alzheimer’s disease, covering its causes, symptoms, diagnosis, treatment options, and caregiving strategies.
Recent data reveal that transfeminine adults experience significantly higher prevalence of Alzheimer’s disease and related dementias compared to matched cisgender peers, independent of gender-affirming hormone therapy, highlighting ur
Recent studies confirm that both childhood and adult lead exposure, especially from gasoline and industrial sources, are associated with increased risk for cognitive decline and dementia in later life.
Limited demographic data transparency in FDA-authorized AI devices for Alzheimer’s may hinder equitable care and generalizability, highlighting a crucial need for improved dataset representativeness and regulatory oversight.
Regular walking and lifestyle interventions slow cognitive decline, especially in APOE ε4 carriers at heightened Alzheimer’s risk, with effects pronounced in women. Evidence underscores the value of simple activity and healthy diet for at-r
Community-based data suggest lecanemab is safe and effective for early-stage Alzheimer’s, with manageable ARIA rates and infusion reactions, particularly in ApoE4 noncarriers.
